HealthPolitics

STAT+: Former Madrigal Pharmaceuticals executive alleges coverup of safety issues tied to its drug

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 05/11/2026, 01:52:24 UTC.

Briefings

A former senior vice president at Madrigal Pharmaceuticals, Michael Charlton, filed a federal lawsuit alleging retaliation after raising safety concerns about his company's drug for MASH patients. The lawsuit claims he was forced to resign in October 2024 and seeks reinstatement or damages under whistleblower protection statutes. The evidence indicates the drug was approved for liver disease, but the specific mechanism of the coverup remains unverified.

Key points

• Michael Charlton served as senior vice president and head of clinical development at Madrigal Pharmaceuticals from October 2024 to January 2026.
• The lawsuit was filed in the Northern District of Illinois on October 9, 2026, seeking reinstatement or monetary damages for alleged retaliation.

Context

The case involves a drug approved for patients with MASH, a liver disease. The evidence highlights a conflict between a senior executive's mandate to ensure clinical trial safety and the company's decision to punish him for raising concerns. This legal action represents a significant challenge to the company's internal governance regarding its flagship medication.

Limitations

The evidence is limited to the lawsuit allegations and does not confirm the existence of a coverup or the specific safety issues raised. The timeline of the drug's approval and the exact nature of the safety concerns remain unverified by the provided source.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 05/11/2026, 11:10:37 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeicl7atz6mudtqoxtvtgat5bhkzlrim2mxvzo5s3tklir7y4jbvhre